NEW YORK – Hematology testing firm PixCell Medical said on Wednesday that it has inked a deal for Medline Industries to distribute PixCell's point-of-care HemoScreen complete blood count analyzer.
The Israeli firm said that the deal with Medline, along with separate agreements signed in recent months with Henry Schein and Thermo Fisher Scientific, will make the analyzer available to healthcare providers, researchers, and laboratories across the US. PixCell officials added that the distribution agreements will make its technologies accessible and affordable across diverse healthcare settings.
"These strategic partnerships align with our commitment to advancing patient care by delivering accurate and timely diagnostic solutions directly to the point of need," PixCell Chief Commercial Officer Guy Frak said in a statement.
The firm secured in 2018 US Food and Drug Administration clearance for its HemoScreen analyzer, and, in April 2023, the firm received an additional 510(k) clearance for direct capillary sampling from a patient's finger without an intermediate tube. That additional clearance allows for easier blood collection without the involvement of a phlebotomist or physician.